Badanie kliniczne nad bezpieczeństwem stosowania censawudyny u pacjentów z zespołem Aicardi-Goutièresa (AGS)

Aicardi-Goutières Syndrome (AGS) is a rare genetic disorder that affects the brain and immune system. It can cause symptoms like developmental delays, problems with movement, and skin issues. This study is looking at a new treatment called censavudine, also known by the code name TPN-101. The treatment is in the form of a powder that is mixed with liquid and taken by mouth. The main goal of the study is to see if TPN-101 is safe for people with AGS and if it can help reduce certain immune system signals that are higher in people with this condition.

The study will involve participants of different ages, from young children to adults, who have been diagnosed with AGS. Participants will receive TPN-101 for up to 48 weeks. During this time, researchers will monitor the participants to see how their bodies respond to the treatment and to check for any side effects. The study will also measure changes in specific markers in the blood that are related to the immune system and brain function.

By the end of the study, researchers hope to gather enough information to understand how TPN-101 works in people with AGS and to determine its safety and effectiveness. This could lead to new treatment options for those affected by this challenging condition.